What is the recommended treatment for smallpox, including antiviral therapy, supportive care, and post‑exposure vaccination?

Smallpox: Definitive Treatment, Supportive Care, and Post‑Exposure Vaccination

Bolded Recommendation

• Treat clinically suspected or confirmed smallpox with immediate isolation, urgent post‑exposure vaccination of contacts within 3–7 days, and initiate tecovirimat as the first‑line antiviral for patients with severe disease or high‑risk features; provide aggressive supportive care throughout 1, 2.

1) Immediate Actions (to reduce mortality, morbidity, and transmission)

• Isolation and infection control:
  • Airborne/contact precautions; cohort or negative pressure if available 3.
  • Rapid case reporting to public health; initiate ring vaccination and contact tracing 3.
• Define contacts and vaccinate within 3 days (best) and up to 7 days after exposure to prevent or attenuate disease 1.

2) Antiviral Therapy (prioritize agents with highest-quality, most recent support)

• First line: Tecovirimat (TPOXX)
  • Rationale: FDA‑approved for treatment of smallpox; strongest, most recent high‑quality evidence base among antivirals; stockpiled for outbreak response 2.
  • Use for: confirmed/probable smallpox, especially severe disease (e.g., hemorrhagic, confluent/flat smallpox), immunocompromise, pediatric, pregnancy, or progressive illness to reduce mortality risk 2.
• Alternatives/adjuncts when severe or refractory, or if TPOXX unavailable:
  • Brincidofovir or cidofovir (consider nephrotoxicity for cidofovir; ensure renal monitoring). Human efficacy evidence is limited; animal/POC data support anti‑orthopox activity 4, 5.
• Caveats/pitfalls:
  • Do not delay initiation in severe/high‑risk cases while awaiting confirmatory testing.
  • Monitor for resistance if prolonged therapy or poor response; consult public health labs for sequencing when feasible 4.
  • Adjust for renal function and drug interactions (notably with cidofovir) 4.

3) Supportive Care (drives survival)

• Fluid/electrolyte resuscitation; nutrition.
• Antipyretics, analgesia; manage vomiting/diarrhea.
• Treat bacterial superinfection of skin lesions with appropriate antibiotics.
• Eye involvement: urgent ophthalmology; lubricants, consider topical antivirals if vaccinia‑related; avoid topical steroids unless specialist‑directed 6.
• Critical care for severe forms (hemorrhagic, malignant/flat, encephalitis): hemodynamic and respiratory support, seizure control 3.

4) Post‑Exposure Vaccination (PEP)

• Primary strategy for outbreak control and mortality reduction: ring vaccination with replication‑competent vaccinia vaccines (ACAM2000/APSV) for exposed persons unless severely immunodeficient 1.
  • Best efficacy: within 3 days of exposure; partial benefit up to 7 days 1.
• Severely immunodeficient (e.g., recent BMT <4 months, HIV CD4 <50, SCID, complete DiGeorge):
  • Avoid replication‑competent vaccines; consider MVA‑based vaccine (JYNNEOS/Imvamune) if antivirals not immediately available or as directed by authorities 1.
• Relative contraindications (e.g., eczema/atopic dermatitis, HIV CD4 50–199, other immunocompromise, vaccine allergy):
  • Prefer MVA (JYNNEOS/Imvamune) when authorized during the response 1.
• Key pitfalls:
  • In a true post‑event setting, there are no absolute contraindications to vaccination except severe immunodeficiency—do not miss the 3–7 day window 1.

5) Management of Vaccine Adverse Events (if they occur during the response)

• Use vaccinia immune globulin (VIGIV) as first‑line for serious complications: eczema vaccinatum, progressive vaccinia, severe generalized vaccinia; consider adjunct cidofovir if refractory or severe 6.
• Strict infection‑control for vaccinees to prevent vaccinia transmission from the vaccination site (hand hygiene, bandage handling) 6.
• CNS adverse events post‑vaccination: supportive/ICU care; no specific antiviral proven effective 6.

6) Practical Algorithm

• Suspect/confirm smallpox → isolate → notify public health 3.
• Assess severity/risk: severe disease, pregnancy, immunocompromise, infants, extensive lesions.
• Start antivirals:
  • Tecovirimat now for severe/high‑risk; consider for all confirmed cases given lethality profile 2.
  • If unavailable/contraindicated or nonresponse: consider brincidofovir or cidofovir with renal precautions 4, 5.
• Provide aggressive supportive care and manage complications 3.
• Ring vaccinate close contacts:
  • ACAM2000/APSV within 3 days (up to 7); if severe immunodeficiency, use MVA (JYNNEOS/Imvamune) per CDC authorization or consider if antivirals not immediately available 1.
• Monitor for vaccine adverse events; use VIGIV for serious reactions 6.

7) Why this recommendation

• Guideline priority: CDC MMWR post‑event vaccine guidance (2015) directs outbreak control and vaccine selection, including exceptions for severe immunodeficiency, which most affects mortality/QOL 1.
• Highest‑quality, most recent antiviral evidence: Tecovirimat FDA approval and expert review support its use and stockpiling for smallpox treatment, outweighing older/POC data for cidofovir/brincidofovir 2.
• Classic outbreak control principles (isolation, surveillance, focused vaccination) remain foundational for reducing deaths and spread 3.

Common pitfalls to avoid:

• Delaying vaccination of contacts beyond 3 days.
• Withholding vaccination in post‑event setting due to routine contraindications—only severe immunodeficiency changes product choice 1.
• Neglecting supportive care intensity, which is decisive for survival.
• Using replication‑competent vaccines in severely immunodeficient persons; prefer MVA where authorized 1.